Publication Name	World Journal of Gastroenterology
Manuscript ID	5490
Country	China

Received	2013-09-10 12:26
Peer-Review Started	2013-09-12 17:09
To Make the First Decision	2013-09-27 16:26
Return for Revision	2013-10-08 12:17
Revised	2013-10-26 10:44
Second Decision	2013-11-13 11:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-11-13 14:50
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-12-11 20:53
Publish the Manuscript Online	2014-01-20 16:41

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection
Manuscript Source	Invited Manuscript
All Author List	Tao Lu, Wai-Kay Seto, Ran-Xu Zhu, Ching-Lung Lai and Man-Fung Yuen
Funding Agency and Grant Number
Corresponding Author	Man-Fung Yuen, MD, PhD, Professor, Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, China. mfyuen@hkucc.hku.hk
Key Words	Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Vaccination; Prevention
Core Tip	Hepatocellular carcinoma (HCC), with the majority of cases associated with infection from hepatitis B virus (HBV) or hepatitis C virus (HCV), is the most common primary liver tumor. We introduced risk factors and risk predictive scores associated with HCC development among chronic HBV and HCV infection for its early diagnose and prevention. Vaccination plays a central role in the prevention of HBV-related HCC. Treatment of chronic HBV infection, especially by nucleoside analogue therapy, could reduce the risk of HBV-related HCC. Pegylated interferon and ribavirin could reduce the risk of HCV-related HCC. Chemopreventive agents in reducing HBV- and HCV-related HCC were also discussed.
Publish Date	2014-01-20 16:41
Citation	Lu T, Seto WK, Zhu RX, Lai CL, Yuen MF. Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J Gastroenterol 2013; 19(47): 8887-8894
URL	http://www.wjgnet.com/1007-9327/full/v19/i47/8887.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i47.8887

Full Article (PDF)	WJG-19-8887.pdf
Manuscript File	5490-Review.docx
Answering Reviewers	5490-Answering reviewers.pdf
Copyright License Agreement	5490-Copyright assignment.pdf
Peer-review Report	5490-Peer reviews.pdf
Scientific Editor Work List	5490-Scientific editor work list.doc